{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:52:55Z","timestamp":1789087975215,"version":"build-2803163510"},"reference-count":28,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Over the last decade, the treatment landscape for moderate to severe psoriasis has undergone transformative changes with the advent of biotechnological drugs. Monoclonal antibodies targeting the IL-17 and IL-23 pathways have displayed remarkable clinical efficacy and safety, even among patients with complex comorbidities. These innovations have extended across various age groups within the psoriatic population. However, a scarcity of age-specific data remains regarding the efficacy and safety of these medications. Our study tries to bridge this gap by systematically presenting data obtained from the analysis of 1055 patients treated for psoriasis with anti-IL17 and anti-IL23 drugs during a 1-year period. The effectiveness and safety of anti-IL-17 and anti-IL23 drugs for moderate to severe psoriasis were assessed across four different age groups ranging from patients less than 26 years old to patients older than 65 years, divided in four year ranges. In the studied population, baseline PASI score was significantly higher in the age group of individuals over 65 years compared to those under 26 years old. Patients over 65 years also exhibited a slower rate of improvement in PASI-90 and PASI &lt; 3 at the 16-week mark compared to other age groups. However, no clinically significant differences in treatment response were found when comparing overall responses among different age groups. In age groups older than 26 years, anti-IL17 drugs seems faster in the achievement of PASI-100 when compared to anti-IL23 drugs. This trend became more pronounced with increasing age. The investigation provides insights into treatment responses and patient characteristics, highlighting the influence of age as a significant variable in patient management.<\/jats:p>","DOI":"10.3390\/jcm12237215","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:12:13Z","timestamp":1700568733000},"page":"7215","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Francois","family":"Rosset","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-3219","authenticated-orcid":false,"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-1406","authenticated-orcid":false,"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and Treatment: Past, Present and Future Aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s13555-023-00949-5","article-title":"Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel","volume":"13","author":"Papp","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14712598.2023.2236023","article-title":"Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): A retrospective, observational, single-center, real-life study","volume":"23","author":"Mastorino","year":"2023","journal-title":"Expert Opin Biol Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_6","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"2022","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"adv00215","DOI":"10.2340\/00015555-3569","article-title":"Disease and Treatment Characteristics in Geriatric Psoriasis: A Patient Survey Comparing Age Groups","volume":"100","author":"Winden","year":"2020","journal-title":"Acta Derm.-Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: Guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/exd.14822","article-title":"Impact of comorbidities in elderly and frail patients and response to biological therapy in psoriasis","volume":"32","author":"Rosset","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjd.15645","article-title":"Biologics for psoriasis: More drugs, new patient categories, but fresh challenges for clinical dermatologists","volume":"177","author":"Pink","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","article-title":"Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting","volume":"40","author":"Lynde","year":"2023","journal-title":"Adv Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/1346-8138.16702","article-title":"Biologics in pediatric psoriasis","volume":"50","author":"Wang","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ad.2021.05.017","article-title":"Psoriasis moderada-grave en pacientes pedi\u00e1tricos y j\u00f3venes: Experiencia en el registro BIOBADADERM","volume":"113","author":"Benito","year":"2021","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pop.2015.10.002","article-title":"Obesity in Older Adults","volume":"43","author":"Kalish","year":"2016","journal-title":"Prim. Care Clin. Off. Prac."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/ced.14258","article-title":"Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period","volume":"45","author":"Megna","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40266-014-0156-6","article-title":"Managing Moderate-to-Severe Psoriasis in the Elderly","volume":"31","author":"Balato","year":"2014","journal-title":"Drugs Aging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1286251","DOI":"10.3389\/fimmu.2023.1286251","article-title":"The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis","volume":"14","author":"Fukasawa","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s13555-023-00973-5","article-title":"Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries","volume":"13","author":"Balieva","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e838","DOI":"10.1111\/jdv.18314","article-title":"Risankizumab shows faster response in bio na\u00efve than in bio-experienced psoriatic patients","volume":"36","author":"Mastorino","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/jdv.18042","article-title":"Anti-drug antibodies of IL-23 inhibitors for psoriasis: A systematic review","volume":"36","author":"Norden","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e15697","DOI":"10.1111\/dth.15697","article-title":"Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40261-023-01271-w","article-title":"Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It?","volume":"43","author":"Gargiulo","year":"2023","journal-title":"Clin. Drug Investig."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7215\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:18Z","timestamp":1760131578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/23\/7215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":28,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["jcm12237215"],"URL":"https:\/\/doi.org\/10.3390\/jcm12237215","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}